Asset Details
Do you wish to reserve the book?
Detection of novel Fabry disease‐associated pathogenic variants in Japanese patients by newborn and high‐risk screening
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Detection of novel Fabry disease‐associated pathogenic variants in Japanese patients by newborn and high‐risk screening
Do you wish to request the book?
Detection of novel Fabry disease‐associated pathogenic variants in Japanese patients by newborn and high‐risk screening
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Detection of novel Fabry disease‐associated pathogenic variants in Japanese patients by newborn and high‐risk screening
2020
Overview
Background
In Japan, newborn and high‐risk screening for Fabry disease (FD), an inherited X‐linked disorder caused by GLA mutations, using dried blood spots was initiated in 2006. In newborn screening, 599,711 newborns were screened by December 2018, and 57 newborns from 54 families with 26 FD‐associated variants were detected. In high‐risk screening, 18,235 individuals who had symptoms and/or a family history of FD were screened by March 2019, and 236 individuals from 143 families with 101 FD‐associated variants were detected. Totally 3, 116 variants were detected; 41 of these were not registered in Fabry‐database.org or ClinVar and 33 were definitely novel. Herein, we report the clinical outcomes and discuss the pathogenicity of the 41 variants.
Methods
We traced nine newborns and 46 individuals with the 33 novel variants, and nine newborns and 10 individuals with eight other variants not registered in the FD database, and analyzed the information on symptoms, treatments, and outcomes.
Results
Thirty‐eight of the 46 individuals with the 33 novel variants showed symptoms and received enzyme‐replacement therapy and/or chaperone treatment.
Conclusion
Delayed diagnosis should be avoided in patients with FD. Our results will help clinicians diagnose FD and determine the appropriate treatment for patients with these variants.
Nine newborns and 46 individuals with 33 novel variants, and nine newborns and 10 individuals with eight other variants not registered in the FD database were traced and the information on symptoms, treatments, and outcomes was analyzed. Thirty‐eight of 46 individuals with 33 novel variants had symptoms and received enzyme replacement therapy and/or chaperone treatment.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Disease
/ Dried Blood Spot Testing - methods
/ Dried Blood Spot Testing - standards
/ Dried Blood Spot Testing - statistics & numerical data
/ Female
/ Genetic Testing - statistics & numerical data
/ Genetics
/ Genomes
/ Humans
/ Infant
/ Japan
/ Male
/ Mutation
/ Neonatal Screening - methods
/ Neonatal Screening - standards
/ Neonates
/ Original
/ Patients
/ Risk
/ Software
